Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAILOR trial of erlotinib versus docetaxel in EGFR wild-type advanced non-small cell lung cancer
2007-004786-17Phase 3Completed
- Sponsor
- ASST Fatebenefratelli Sacco
- Start
- Oct 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Tarceva with docetaxel (2 arms). Primary endpoint: overall survival. Started Oct 2007; status: completed.
02
Drugs
erlotinibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-004786-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004786-17.